A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH

The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.

Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.